The lead candidate, claseprubart, is a subcutaneous antibody that selectively inhibits active C1s. In chronic inflammatory demyelinating polyneuropathy (CIDP), the company reported a 75% response rate in the interim analysis of the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial, …
The company described the May 2026 four-week intravenous data as positive. At the 1 mpk dose (four patients), mean improvements from baseline were 6.4 points on the mFARS scale and 2.7 points on the upright stability score. Whole blood FXN mRNA rose 65% from …
Prescription gammaCore for primary headache and Quell Fibromyalgia are the two leading products, with Truvaga and TAC-STIM serving the general wellness and human performance markets. The company said the majority of 2026Revenuecontinues to come from prescription sales to the VA. Sales to the UK …
In the United States, purchases of receivable portfolios at MCM were USD 309.95 million against USD 261.14 million, a rise the company attributed to supply and pricing. In Europe, Cabot purchases were USD 79.70 million against USD 84.93 million. Total purchases were USD 389.66 …
Revenue was USD 297.21 million, against USD 329.3 million in the second quarter of 2026 and USD 391.0 million in the third quarter of 2025. Management's commentary linked the year-over-year change in earnings to the new charter in Jordan, partly offset by the timing …
Chief executive Laurence Penn said the company benefited from retained tranches of non-QM and Agency-eligible securitizations, commercialMortgagebridge loans and corporate credit, and that loan originator investments, particularly LendSure, contributed to results. Its residential loan portal connected with 57 sellers and generated USD 1.6 billion …
Service revenue was a record USD 187.8 million against USD 179.1 million. The company said usage-based offerings drove that result, with platform usage revenue up 51% year over year.
Net sales increased 51%, which the company tied to both retailer andE-commercechannels in the United States and internationally. Gross margin rose by approximately 160 basis points to 71%. The company said that included approximately 30 basis points from incremental IEEPATariffrefunds flowing through cost of …
The company said it now holds exclusive rights to commercialize Evolysse in every market where it sells Jeuveau. The Symatese amendments carry upfront payments of EUR 1.4 million, paid in the quarter, and potential additional payments of up to EUR 2.9 million tied to …
Original equipment manufacturer revenue was USD 6.22 million against USD 8.96 million, a 31% decrease, and aftermarket revenue was USD 4.04 million against USD 4.64 million, down 13%. The company attributed the megaproject decline to lower shipments to Africa, Asia and the Middle East. …